# A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

> **NCT07117487** · PHASE3 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 507 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** mRNA-1345

## Key facts

- **NCT ID:** NCT07117487
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-05
- **Primary completion:** 2026-03-27
- **Final completion:** 2026-03-27
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07117487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07117487, "A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07117487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*